LYEL — Lyell Immunopharma Inc

Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on NASDAQ. It is led by Lynn Seely M.D., Ph.D., based in 201 Haskins Way, South San Francisco, CA, United States, 94080, with about 300 employees. Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Latest reported LYEL revenue for 2025-09-30 was $15.0K. Net income was -$38.8M. Revenue was up 87.5% from 2025-06-30 to 2025-09-30. LYEL currently screens at market cap $143.5M.

Use this LYEL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LYEL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LYEL SEC filings page. Lician reads the product cache first so this HTML stays unique to Lyell Immunopharma Inc even when a live quote feed is slow.